Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study
August 2023 | Volume 22 | Issue 8 | 754 | Copyright © August 2023
Published online July 25, 2023
Jayme Heim MSN FNP-BCa, J. Gabriel Vasquez MDa, Brad Schenkel MSb, Neal Bhatia MDc
aWest Michigan Dermatology, Grandville, MI
bSun Pharmaceutical Industries, Inc., Princeton, NJ
cTherapeutics Clinical Research, San Diego, CA